ArticleScientific reports2022

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.

Seyed Pairawan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.